Skip to main content
SCYNEXIS INC logo

SCYNEXIS INC - Investor Relations & Filings

Listed IPO Nov 2014
Ticker · SCYX ISIN · US8112922005 LEI · 529900XBHFGMNTU70154 US Manufacturing
Open in API
Filings indexed 685 across all filing types
Latest filing 2025-11-12 Major Shareholding Noti…
Country US United States of America
Listing US SCYX · 7 venues

About SCYNEXIS INC

https://www.scynexis.com/

SCYNEXIS, Inc. is a biotechnology company focused on the discovery and development of novel anti-infectives to overcome difficult-to-treat and drug-resistant fungal infections. The company is pioneering a new class of broad-spectrum antifungal agents called 'fungerps,' which are triterpenoid-based compounds. These agents are being developed in both oral and intravenous formulations to treat a range of serious, invasive, and life-threatening fungal diseases, particularly those encountered in hospital environments. SCYNEXIS aims to address the significant global health threat of antifungal resistance by providing innovative therapeutic options where existing treatments are limited or ineffective. The company's development pipeline includes second-generation fungerp candidates.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-12 English
10-Q
Interim / Quarterly Report 9M 2025
2025-11-05 English
4
Director's Dealing
2025-10-21 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements. The text describes the entry into a material definitive agreement (a binding memorandum of understanding amending an exclusive license agreement). It does not contain financial statements or detailed financial performance data, nor is it an earnings release or management discussion. It is not an annual or interim report, nor a proxy or voting result. The document is a regulatory filing announcing a material contract event, typical of Form 8-K filings. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and content support this classification with high confidence.
2025-10-15 English
10-Q
Interim / Quarterly Report Q2 2025
2025-08-13 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 25, 2025, reporting the submission of matters to a vote of security holders at the company's 2025 Annual Meeting of Stockholders. It includes detailed voting results on director elections, appointment of the independent auditor, and advisory approval of executive compensation. The content focuses on the official results of shareholder votes at the annual meeting. The document length is 4395 characters, which is relatively short but contains substantive voting data, not just an announcement or a link to a report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-07-01 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.